Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neoadjuvant Gemcitabine and Cisplatin in Combination With Perioperative Pembrolizumab Versus Upfront Surgery for Patients With Primary Resectable and Borderline Resectable Perihilar and Distal Cholangiocarcinoma (NEODISCO): A Multicentre Phase 2B/3 Randomized Controlled Trial

NCT06923475 is registered in ClinicalTrials.gov with Amsterdam UMC, location VUmc as lead sponsor.

NCT NCT06923475
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06923475 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neoadjuvant Gemcitabine and Cisplatin in Combination With Perioperative Pembrolizumab Versus Upfront Surgery for Patients With Primary Resectable and Borderline Resectable Perihilar and Distal Cholangiocarcinoma (NEODISCO): A Multicentre Phase 2B/3 Randomized Controlled Trial
Lead sponsor
Amsterdam UMC, location VUmc
Phase
Phase 2/3
Overall status
Recruiting
Start date
April 17, 2026
Completion date
November 6, 2028
Enrollment
150 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

borderline resectable, distal cholangiocarcinoma, extrahepatic cholangiocarcinoma, perihilar cholangiocarcinoma, resectable